HHS Public Access Author manuscript Author Manuscript

Ann Surg Oncol. Author manuscript; available in PMC 2015 October 01. Published in final edited form as: Ann Surg Oncol. 2015 October ; 22(10): 3264–3272. doi:10.1245/s10434-015-4668-z.

Adjuvant endocrine therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005-2012 in the National Cancer Database Meghan R. Flanagan, MD1, Mara H. Rendi, MD, PhD2, Vijayakrishna K. Gadi, MD, PhD3,4, Kristine E. Calhoun, MD1, Kenneth W. Gow, MD1,5, and Sara H. Javid, MD1

Author Manuscript

1University

of Washington, Department of Surgery, Seattle, Washington

2University

of Washington, Department of Anatomic Pathology, Seattle, Washington

3University

of Washington, Department of Medicine, Seattle, Washington

4Fred

Hutchinson Cancer Research Center, Clinical Research and Public Health Sciences Divisions, Seattle, Washington

5Seattle

Children's Hospital, Seattle, Washington

Abstract

Author Manuscript

Background—Adjuvant endocrine therapy (AET) has been shown to reduce the risk of second breast cancer events in women with ductal carcinoma in situ (DCIS). There is no population-level evaluation of AET use in DCIS patients subsequent to standardized reporting of estrogen receptor (ER) status in cancer registries in 2004. Methods—We conducted a retrospective cohort study of women with DCIS in the National Cancer Database between 2005 and 2012. Patient, tumor and treatment characteristics, and temporal trends associated with receipt of AET were evaluated using generalized linear regression.

Author Manuscript

Results—Among 206,255 DCIS patients, 36.5% received AET. Fewer than half of ER+ patients (n=62,146, 46.4%) received AET with a modest but significant increase over time (43.6% in 2005 to 47.5% in 2012; unadjusted p-trend